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         Multiple  myeloma  (MM) cells  interact  with  bone  marrow stromal 
cells stimulating transcription and secretion of cytokines like IL-6 and IL-10, 
which are implicated in the progression and dissemination of MM. Regulation 
of cytokines secretion is under genetic control through genetic polymorphisms 
in  their  coding  and  promoter  sequences.  It  seems  that  single  nucleotide 
polymorphism (SNP) in the promoter region of various genes may regulate the 
plasma concentrations of cytokines. Cytokines could be also hypothesized to 
function  as  pain  modulators  as  peripheral  nociceptors  are  sensitized  by 
cytokines. The aim was to determine if the SNP of IL-6 and IL-10 cytokines 
could  influence  the  analgesic  response  of  radiotherapy  in  the  treatment  of 
painful bone destructions in MM patients. 30 patients (19 women and 11 men, 
median age: 67 years) with MM and painful bone destructions were treated 
with  palliative  radiotherapy.  Pain  was  evaluated  according  to  the  visual 
analogue  scale  and  analgesics  intake.  Pain  scores  and  analgesics  use  were 
measured prior to radiotherapy as well as 4, 12 and 24 weeks afterward. Opioid 456                                                                                                            GENETIKA, Vol. 46, No.2, 455-469, 2014 
analgesics  were  converted  to  the  morphine-equivalent  daily  dose  (MEDD). 
Genomic DNA was extracted from peripheral blood leukocytes and IL-6 and 
IL-10  gene  promoter  polymorphisms  were  analysed  with  polymerase  chain 
reaction.  60%  of patients  reported  severe  pain  prior  to radiotherapy,  which 
decreased  to  13%  at  the  first  follow-up  visit  (p  <0.001).  The  MEDD  on 
admission to the hospital was 75 mg/day which decreased to 46 mg/day at the 
first follow-up visit (p = 0.033). A significant parameter in pain relief was: age 
< 65 years (p=0.029). We analysed 6 SNPs in the gene promoter region of IL-6 
(-597 G/A, -572 G/C, -174 G/C) and IL-10 (-592 A/C, -819 C/T, -1082 A/G) as 
well as their relation with pain severity and analgesic consumption. Patients 
who are IL-10 -1082 A/G carriers are prone to respond better to radiotherapy 
than other patients (p<0.05). A borderline association was noted for patients 
who are IL-6 -597 A/A and G/G carriers - assumed to be at higher risk for 
severe pain prior to radiotherapy (p=0.07) while for patients who are IL-10 -
1082 A/A carries: the median pain score decreased faster (p=0.08). Patients 
with genotypes IL-6 -597 A/A and IL-6 -174 C/C required a smaller dose of 
opioids (p=0.06). SNP of IL-6 and IL-10 cytokines can influence the analgesic 
response  of  radiotherapy.  Patients  with  genotype  IL-10  -1082 A/G respond 
better to radiotherapy. 
Key words: Multiple myeloma, single gene polymorphism, pain relief. 
 
INTRODUCTION 
Multiple  myeloma  (MM)  is  a  clonal  plasma  cell  neoplasm  derived  from  an  early 
precursor  of  B  cell  lineage  characterized  by  anaemia,  renal  impairment,  painful  bone 
destructions and hypercalcaemia. The growth of MM cells is dependent on a complex interaction 
between growth factors, adhesion molecules, plasma cells and bone marrow stromal cells. MM 
cells  interact  with  bone  marrow  stromal  cells  stimulating  transcription  and  secretion  of 
cytokines,  which  are  implicated  in  the  progression  and  dissemination  of  MM.  The  role  of 
interleukin-6 (IL-6) and interleukin-10 (IL-10) is well established in MM pathogenesis (LAUTA 
2001, ZHENG et al, 2008, KLEIN et al, 1999, LAUTA 2003, URBANSKA-RYS et al, 2000). 
IL-6 is a cytokine produced by different cells: leukocytes, adipocytes, endothelial cells, 
fibroblasts, and myocytes. It plays a role in the pathogenesis of inflammation, autoimmune and 
lymphoproliferative diseases. IL-6, which is produced via an autocrine mechanism by MM cells 
itself,  is  one  of  the  most  important  cytokines  that  contributes  to  MM  cells  survival  and 
proliferation, whereas the paracrine mechanism is believed to be involved in the production of 
IL-6 in a microenvironment in the bone marrow (LAUTA 2001, LAUTA 2003). Production control 
of IL-6 may be exerted by other interleukins such as Interleukin-1beta (IL-1β) and IL-10 as well 
(ZHENG et al, 2008). 
IL-10 is a cytokine produced by macrophages, T cells, B cells, natural killer cells and 
mast  cells  (ZHENG  et  al.  2001).  IL-10  is  described  as  the  most  potent  factor  of  B-cell 
differentiation and an important growth factor of MM cells (LU et al. 1995) associated by the 
induction of an oncostatin M autocrine loop (Gu et al. 1996). 
Increased serums levels of IL-6 and IL-10 are observed in MM patients. High serum 
level of IL-6 correlate with the stage of MM and degree of bone destruction (DUVILLARD et al. 
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increased serum levels of IL-6 levels have been associated with a poor prognosis (LAUTA. 2003). 
High serum levels of IL-10 correlate with progressive MM disease (WIERZBOWSKA et al. 1999). 
Furthermore,  higher  serum  IL-10  levels  correlates  with  higher  IL-6  levels  in  MM  patients 
(URBANSKA-RYS et al. 2000). 
Regulation  of  cytokine  secretion  is  under  genetic  control  through  genetic 
polymorphisms  in  their  promoter  sequences.  It  seems  that  single  nucleotide  polymorphism 
(SNP)  in  the  promoter  region  of  the  IL-6  gene  at  position  -174  may  regulate  the  plasma 
concentrations  of  IL-6  (BENNERMO  et  al.  2004,  ENDLER  et  al.  2004).  The  CC  genotype  is 
considered to be a low producer and GG genotype a high producer of IL-6 (ZHENG et al, 2008, 
OLOMOLAIYE et  al. 1998). The IL-10.G  genotype 136/136 is associated with most increased 
secretion of IL-10 among patients with MM (ZHENG et al, 2001). But there was no relation 
between SNP at the position -1082, -819 or -592 and the disease expression (ZHENG et al, 2001, 
MAZUR et al. 2005).  
Peripheral  nociceptors  are  sensitized  by  cytokines  that  are  produced  in  response  to 
cancer  or  its  cytostatic  treatment.  Cytokines  released  by  activated  glial  cells,  cause  hyper 
excitability  in  pain  transmitting  neurons,  increase  the  release  of  substance  P  and  excitatory 
amino acids from presynaptic terminals triggering a high pain response (WATKINS et al. 2005, 
WATKINS et al. 1995, WATKINS et al. 1994). Cytokines could be also hypothesized to function as 
pain modulators. This is one of the main direct mechanisms leading to hyperalgesia in chronic 
disease (JUNGER et al. 2000). An analytic literature review revealed some studies that suggest 
variants  in  cytokines  genes,  which  could  explain  the  individual  variations  in  reported  pain 
severity and analgesic response among cancer patients (REYES-GIBBY et al. 2013, REYES-GIBBY et 
al. 2009, REYES-GIBBY et al. 2008, REYES-GIBBY et al. 2007, MCCANN et al. 2012, ILLI et al. 
2012, SVETLIK et al. 2013, REYES-GIBBY et al. 2009, RAUSCH et al. 2010). The aim of this study 
was to determine if the SNP of IL-6 and IL-10 cytokines could influence the analgesic response 
of radiotherapy in the treatment of painful bone destructions in MM patients. 
 
MATERIALS AND METHODS 
Patient’s characteristics 
30 patients (19 women and 11 men, median age: 67 years, 51 – 83 years) with multiple 
myeloma and painful bone destructions were enrolled into the study, which was conducted at the 
Department of Oncology and Haematology at the Hospital of Lithuanian University of Health 
Science from September 2012 until September 2013. According to the Durie and Salmon staging 
system (DURIE et al. 1975) three patients (10%) with stage II and 27 (90%) patients with stage III 
MM (disease) were classified. Fifteen (50%) patients were identified with IgG type M protein, 7 
(23%) patients for IgA type and 8 (27%) patients with light chains type MM. Inclusion criteria: 
patients  diagnosed  with  symptomatic  multiple  myeloma,  proved  by  histological  data, 
electrophoresis  and  immunofixation  of  serum  and  urine  as  well  as  patients,  with  bone 
destructions verified by bone X-ray, computed tomography (CT) resulting in subjective pain 
perception or an impending fracture accompanied by a Karnofsky Index above 40 were included. 
Exclusion  criteria:  patients  with  bone  metastases  from  solid  tumors,  patients  with  solitary 
plasmacytoma, patients who had previously received irradiation to the same site of destruction 
site, and patients of poor health state were excluded from the study. Patients with painful bone 
destructions were treated with palliative radiotherapy. They were randomized into two arms: 12 
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with 30 Gy in a 10 fractions regimen. Twenty two (73%) irradiated sites included the spinal 
column, 5 (17%) the pelvic bone and 3 (10%) the extremities. 28 patients (93%) were treated 
with  concurrent  chemotherapy.  Surgery  was  performed  prior  to  radiotherapy  for  9  (30%) 
patients. Patient’s characteristics are shown in Table 1a,b and c. 
 
Table 1a.Patients characteristics.  
Characteristics  N = 30  % 
Sex     
Male  11  37 
Female  19  63 
Age (years)     
Range  51 - 83   
Median   67   
Clinical stage (Durie and  Salmon)     
II  3  10 
III  27  90 
Karnofsky Index (%)  50 - 80   
Median   60    
Paraprotein     
IgG  15  50 
IgA  7  23 
Light chain  8  27 
SE: standard error of mean 
 
Table 1b.Patients characteristics. 
Characteristics    N = 30  % 
Irradiated sites     
Spinal vertebrae  22  73 
Pelvic bone  5  17 
Extremites  3  10 
Surgery     
Yes  9  30 
No  21  70 
Concurrent chemotherapy     
Yes  28  93 
No  2  7 
Pain score at admission     
2-4  5  17 
5-7  7  23 
8-10  18  60 
Pain medication  %   
Non-opioids  4  13 
Opioids  26  87 
SE: standard error of mean M.RUDZIANSKIENE et al: SNP INFLUENCE PAIN RELIEF                                                                      459 
Table 1c.Patients characteristics. 
Characteristics  N = 30    % 
Opioids dose (mg/day)     
Mean  71   
Range  10 - 260   
Radiotherapy regimen     
8 Gy one fraction  12  40 
30 Gy in 10 fractions  18  60 
SE: standard error of mean 
 
 
Pain was evaluated according to the visual analogue scale (VAS) with scale endpoints 
ranging from 0 (no pain at all) to 10 (worst imaginable pain) (JENSEN et al. 1986). Pain scores ≤ 
4 were classified as mild, 5 – 7 as moderate and ≥ 8 as severe (CHOW et al. 2006). Pain scores 
and analgesics use were measured prior to initiation of treatment and at 4, 12 and 24 weeks after 
radiotherapy.  Medication  was  classified  into  two  groups:  non-opioids  and  opioids.  Opioid 
analgesics were converted to the morphine-equivalent daily dose (mg/day) (SELBY and  YORK 
PALLIATIVE CARE TEAM and PHARMACY GROUP, 2011). 
Genotyping  of  IL-6  and  IL-10  Genomic  DNA  was  extracted from peripheral  blood 
leukocytes with the help of an commercially available DNA extraction kit (GeneJet Genomic 
DNA Purification kit, Thermo Fisher Scientific), following the manufacturer‘s instructions. IL-6 
and  Il-10  gene  promoter  polymorphisms  were  analysed  with  polymerase  chain  reaction-
restriction fragment length polymorphism assay (PCR-RFLP). 
IL-6 gene region including -597 G/A and -572 G/C polymorphic sites were amplified 
by using primers reported by K. Snoussi et al. (SNOUSSI et al. 2005). Earlier described PCR 
conditions were slightly modified. Briefly, PCR reaction was carried out in a total volume of 25 
µl containing 1x DreamTaq standard buffer, template DNA, 1.2 µM of each primer, 4.0 mM 
MgCl2, 200 µM of each dNTP and 0.65 U of DreamTaq DNA polymerase (Thermo Fisher 
Scientific, Waltham, MA, USA) with annealing at 58 °C. The amplicon was then digested either 
by FokI or MbiI restriction endonucleases (Thermo Fisher Scientific, Waltham, MA, USA) for 
the  detection  of  -597  G/A  and  -572  G/C  polymorphisms,  respectively.  The  length  of  the 
fragments was as indicated by K. Snoussi et al. (SNOUSSI et al. 2005). The primer sequences for 
IL-6 gene -174 G/C polymorphism was as described by C.R. Duch et al. (DUCH et al. 2007). The 
PCR conditions were set according to the  protocol presented above with different annealing 
temperature of 59 °C. NlaIII restriction endonuclease was used for Il-6 -174 G/C genotyping. 
The  fragments  were  separated  electrophoretically  using  2%  agarose  gel  containing  ethidium 
bromide. 
Il-10 gene promoter polymorphisms were analyzed as reported by J. Liu et al (LIU et al. 
2011). For -819 C/T and -592 C/A polymorphisms the same reaction mixture composition was 
used. Briefly, PCR reaction was carried out in a total volume of 25 µl containing 1x DreamTaq 
standard buffer, template DNA, 0.24 µM of each primer, 200 µM of each dNTP and 1.25 U of 
DreamTaq DNA polymerase (Thermo Fisher Scientific, Waltham, MA, USA) with annealing at 
58 °C and 63 °C for -819 C/T and -592 C/A polymorphisms, respectively. The PCR reaction 
conditions  for  Il-10  gene  -1082  G/Apolymorphism  were  slightly  modified  by  adding  4.0 
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C/T  and  -592  C/A  polymorphisms  were  analyzed  using  MnlI,  MaeIII  and  RsaI  restriction 
endonuclease, respectively. The results were visualized on 3% agarose gel containing ethidium 
bromide. 
 
Statistical analysis 
Statistical  data  analysis  was  performed  by  using  the  IBM  SSPS  Statistics  21.0  for 
Windows (SPSS Inc., Chicago, IL, USA). Descriptive statistics were indicated to summarize 
patients’  characteristics  (Table  1).  Chi  squared  test  and  Fisher’s  Exact  test  were  used  for 
identification  of  small  expected  frequencies  permitting  comparison  regarding  proportions  of  
pain reduction among  groups  created  by  socio-demographic  and clinical characteristics. The 
logistic regression was used to evaluate associations between severe pain status or pain relief, 
demographic  and  clinical  variables and  different  genotypes  (Table 2  and  Table  3).  The  Chi 
squared test (Fisher’s Exact test (or Chi square exact test) for small expected frequencies was 
used to compare pain severity proportions among different genotype groups. McNemar test was 
used to compare paired proportions of pain severity. The Mann-Whitney U test was used for 
evaluation  of  pain  score  differences  and  analgesic  consumption  between  two  independent 
genotype  groups  and  the  Kruskal-Wallis  test  was  used  for  the  three  independent  genotype 
groups.). Differences between compared characteristics were taken as statistically significant if 
p-value <0.05. 
The study protocol was prepared in accordance with the Helsinki Declaration and was 
approved  by  the  Lithuanian  Regional  Research  Ethics  Committee  and  State  Data  Protection 
Inspectorate. 
 
 
RESULTS  
Sixty percent (18/30) of the patients reported severe pain (>7/10) on admission to the 
hospital which decreased to 13% (4/30) after one month at the first follow up visit (McNemar p 
<0.001). The Mean Morphine Equivalent Daily Dose (MEDD) on admission to the hospital was 
75 mg/day (range 10 – 260 mg/day, median 60) which decreased to 46 mg/day (range 0 – 140 
mg/day,  median  15)  at  the  first follow  up  visit  after  radiotherapy  (Wilcoxon  p  =  0.033).  A 
significant parameter in pain relief was: age < 65 years (p=0.029). Other investigated parameters 
(sex, paraprotein, stage of disease, concurrent chemotherapy, Karnofski Index, hemoglobin level, 
radiotherapy dose) were insignificant. 
Higher pain scores were more prevalent among younger patients (<65 years), in men 
than in women, among those with third stage of  myeloma and with lower Karnofsky  Index 
(<60%) as well as among those patients with IgA and light chains multiple myeloma (Table 2). 
Unfortunately results were statistically not significant due to low sample size. Greater pain relief 
was observed in patients with IgG type multiple myeloma, in men than in women, in patients 
treated with 30 Gy radiotherapy regimen, among patients with poor health status (Karnofski 
Index <60%) and as well as in those with a higher hemoglobin level (>10 g/dL). Due to low 
sample size results are not statistically significant (Table 3). 
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Table 2. Pain severity in patients with multiple myeloma. 
Variable  Pain severity 
Severe/non severe 
OR (95% CI)  p 
Sex       
Male
*  6/5  1.40 (0.24-8.16)  0.7 
Female  12/7     
Age (years)       
<65  6/5  1.69 (0.21-13.75)  0.6 
≥ 65
*  12/7     
Clinical stage (Durie and  Salmon)       
II
*  1/2  3.87 (0.24-63.15)  0.3 
III  17/10     
Karnofsky Index (%)       
<60%   9/3  3.8 (0.55-26.43)  0.2 
≥60%
*  9/9     
Paraprotein       
IgG
*  9/6  1.55(0.24-10.11)  0.6 
IgA and light chain  9/6     
*Reference group 
 
 
Table 3.Pain relief in patients with multiple myeloma 
Variable  OR (95% CI)  p 
Sex     
Male  1.09 (0.08-14.16)  0.9 
Female
*     
Radiotherapy regimen     
30 Gy  5.28 (0.57-48.74)  0.14 
8 Gy
*     
Hemoglobin level (g/dL)     
≤10
*  1.83 (0.16-20.81)  0.6 
>10     
Karnofsky Index (%)     
<60%   1.0 (0.12-8.13)  0.9 
≥60%
*     
Paraprotein     
IgG  1.55(0.16-14.99)  0.7 
IgA and light chain
*     
*Reference group 
 
We analysed 3 SNPs (-597 G/A, -572 G/C, -174 G/C) in IL-6 gene promoter region and 
3 SNPs (-592 A/C, -819 C/T, -1082 A/G) in IL-10 gene promoter and their association with pain 
severity  and  analgesic  consumption.  Most  patients  were  GG  carriers  in  IL6  all  genotyped 462                                                                                                            GENETIKA, Vol. 46, No.2, 455-469, 2014 
promoter positions. The majority of patients were CC carriers at position -592 and -879 and AG 
carriers at position -1082 in IL-10. No significant association between pain severity and different 
genotypes could be found due to a small sample size. An borderline association was evident for 
patients who are IL6 -597 A/A and G/G carries as these are at higher risk of severe pain before 
radiotherapy (p=0.07). All patients with IL6 -572 G/C genotype were at higher risk of severe 
pain, unfortunately no link between this particular genotype and pain could be established as it 
was determined only in two patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure1A. Pain severity in the patients with different genotypes at admission and in follow up 
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Figure 1B. Analgesic consumption at admission and after radiotherapy in the patients with different 
genotypes. 
 
 
In Figure 1A you can see how pain severity decreased in the patients with different 
genotypes. The Mann-Whitney U and Kruskal-Wallis tests were used for evaluation of different 
pain severity scores between different genotype groups on admission to the hospital and one, 
three  and  six  months  after  radiotherapy.  We  did  not  find  a  statistical  significant  difference 
regarding pain scores on admission and during follow up. Nevertheless a borderline association 464                                                                                                            GENETIKA, Vol. 46, No.2, 455-469, 2014 
of  improvement  of  pain  score  for  patients  who  are  IL10 -1082  A/A  carries  was  found:  the 
median  pain  score  decreased  faster  in  those  than  in  other  patients  at  first  month  after 
radiotherapy (p=0.08). The patients with SNP of IL6 -572 G/C are not shown in the plot as there 
were only two patients with genotype IL6 -572 G/C and they died three weeks after the follow 
up. 
The plots in Figure 1B shows analgesic consumption at admission and their decrease at 
one, three and six months after radiotherapy in patients with different genotypes. Unfortunately 
no statistical significant difference was found due to a small sample size but a tendency with 
borderline significance was noted as patients with genotype IL-6 -597 A/A and IL-6 -174 C/C 
required a smaller opioid dose for pain relief (p=0.06 and p=0.06).  
Assessment between radiotherapy response and different patient genotype revealed that 
patients who are IL-10 -1082 A/G carries are prone to respond better to radiotherapy than other 
patients (p<0.05). However, no improvement in the response to radiotherapy was exhibited by 
other genotypes. 
 
DISCUSSION 
It is well know that pain perception, pain relief and analgesic consumption are highly 
individual. Sociodemographic characteristics (age, gender, race) and clinical variables (stage of 
disease, performance status, depressed mood, comorbid conditions) may modify individual pain 
sensation and the response to analgesic treatment. Several mechanisms can be involved in pain 
perception  and  relief:  drug  metabolized  enzymes,  transporters,  receptors,  proinflamatory 
cytokines  and  their  impact  on  genetic  variability.  Peripheral  nociceptors  are  sensitized  by 
cytokines that are produced by inflammatory cells (CD4+ and CD8+ T cells) in response to 
diseases as cancer or its treatment with cytostatics (SVETLIK et al. 2013). This is one of the main 
mechanisms leading to pain hypersensitivity in chronic diseases (JUNGER et al. 2000). Some 
studies demonstrate the impact of SNPs in genes encoding for these cytokines on pain severity 
and pain control in the treatment of various diseases (REYES-GIBBY et al. 2013, REYES-GIBBY et 
al. 2009, REYES-GIBBY et al. 2008, REYES-GIBBY et al. 2007, MCCANN et al. 2012, ILLI et al. 
2012, SVETLIK et al. 2013, REYES-GIBBY et al. 2009, RAUSCH et al. 2010, RAMONDA et al. 2013, 
MIYASHITA et al. 2012, LOO et al. 2012). The current study assessed the impact of selected SNPs 
of IL-6 and IL-10 promoter gene on pain severity in patients with painful bone destructions due 
to multiple myeloma and pain treatment with palliative radiotherapy. We found out that patients 
who were IL-10 -1082 A/G carries responded better to radiotherapy than patients with other 
different  genotypes  (p<0.05)  and  that  there  was  a  borderline  association  for  patients  with 
genotype -1082 A/A in the IL-10 promoter gene, who are prone for faster pain relief (in the first 
four weeks) after performed radiotherapy (p=0.08). According to literature our study is the first 
one to give preliminary evidence that SNPs in cytokine genes associated with pain syndrome in 
multiple myeloma patients play a significant role in respect to radiotherapy response. 
Studies show that about 40% of patients who are treated with active cancer treatment 
report pain which increases up to 80% for patients with advanced stages of cancer (REYES-GIBBY 
et al, 2009, BRUERA et al. 2000, ELSAYEM et al. 2004). REYES-GIBBY et al. observed that patients 
with lung and pancreas cancer with advanced stage of disease and patients at younger age were 
more likely to report severe pain related to their counterparts (REYES-GIBBY et al 2009, REYES-
GIBBY et al 2007, REYES-GIBBY et al 2009). Depressed mood and fatigue significantly correlated 
with pain with different cancers (REYES-GIBBY et al 2009, REYES-GIBBY et al 2007, REYES-GIBBY M.RUDZIANSKIENE et al: SNP INFLUENCE PAIN RELIEF                                                                      465 
et al 2009, STEPANSKI et al 2009). Consisted with other studies we found that sociodemographic, 
clinical characteristics and genetic factors may be relevant in the severity of pain and pain relief. 
Due to a small sample size our study results were not statistically significant, but we observed 
that severe pain was more prevalent among patients younger than 65 years old, in men than in 
women, in those with third stage of MM, with a Karnofsky Index lower 60% and among patients 
with IgA and light chains MM. We also noted a tendency of higher pain relief in patients with 
IgG type MM, more in men than in women, in patients treated with 30 Gy radiotherapy regimen, 
among  patients  with  poor  health  status  (Karnofski  Index  <60%) and  in  those  with  a  higher 
hemoglobin level (>10 g/dL).  
Studies  suggested  that  proinflammatory  cytokines  released  by  activated  glial  cells, 
during  inflammation  or  tissue  damage  modify  the  activity  of  nociceptors  leading  to  pain 
hypersensitivity (WATKINS et al. 2005, WATKINS et al. 1995, WATKINS et al. 1994). A marginal 
significance was noted in our study that multiple myeloma patients who were IL-6 -597 A/A and 
G/G carries had a higher risk of severe pain prior to radiotherapy (p=0.07). In our study there 
were two patients with IL-6 -572 G/C genotype and both of them perceived high pain scores. 
Meanwhile REYES-GIBBY et al. did not find the relationship between IL-6 genotypes and pain 
severity for patients with lung and pancreas cancers (REYES-GIBBY et al. 2008, REYES-GIBBY et 
al. 2009). Variant alleles in TNF-α -308 G/A were significant associated with severe pain in a 
study with lung cancer patients (REYES-GIBBY et al. 2009, REYES-GIBBY et al. 2008), but not in 
adenocarcinoma of the pancreas (REYES-GIBBY et al. 2009). Illi et al. did not find the relation 
between SNPs of TNF-α and IL-6 cytokines in their study and the following symptoms including 
cluster of pain, fatigue, sleep disturbance and depression in oncology patients (ILLI et al, 2012). 
Others  studies  found  that  IL-8  -251  T/A  were  significantly  associated  with  severe  pain  in 
patients with lung and pancreas cancers (REYES-GIBBY et al. 2013, REYES-GIBBY et al. 2007, 
REYES-GIBBY et al. 2009]. A study about lung cancer patients of Rausch et al. found significant 
associations with rs10800871 of IL-10 and the severe pain (RAUSCH et al 2010). However in 
others  studies  the  relationship  between  IL-10  genotypes  and  pain  severity  for  patients  with 
adenocarcinoma  of  the  pancreas  and  lung  cancer  was  not  found  (REYES-GIBBY  et  al.  2013, 
REYES-GIBBY et al. 2009) 
Proinflammatory cytokines released by activated glial cells, but also opioids increase 
glial  production  of  proinflammatory  cytokines,  which  excite  pain  responsive  neurons  and 
counterbalance analgesia by creating compensatory pain relief (REYES-GIBBY et al. 2008). Thus 
effects of cytokines on pain can be bidirectional: increase and facilitation of pain syndrome as 
well as increased opioid tolerance. One study have found out that carriers of the IL-6 -174 C/C 
genotypes required a 4.7 times higher dose of opioids for pain relief related to GG and GC 
genotypes  (p=0.004)  and  no  statistically  significant  tendency  for  higher  MEDD  by 
polymorphisms in IL-8 (REYES-GIBBY et al. 2008). Controversy our findings suggest a marginal 
significance that patients with IL-6-174 C/C and IL-6-597 A/A genotypes required lower doses 
of opioids (p=0.06). The IL-6 -174 G/C polymorphism affects transcription, altering serum levels 
of IL-6 with the C allele associated with significantly lower levels of plasma IL-6 (FISHMAN et al 
1998, TERRY et al. 2000). Our preliminary findings provide that patients who are homozygous 
for the allele associated with lower levels of IL-6 and require lower doses of opioids. Some 
studies showed that IL-6 enters the systemic circulation, where its concentration correlates with 
the severity of injury and subsides days after (DE JONGH et al. 2003).  466                                                                                                            GENETIKA, Vol. 46, No.2, 455-469, 2014 
There are limitations in our study: we have analysed SNPs contribute to pain severity 
and pain relief, but did not valuated symptoms like depression mood and fatigue, which are very 
common in patients with MM and which may have an impact on pain syndrome. We assessed 
only several SNPs of two cytokines genes, there is more genetic variation for each gene, without 
including  multiple  SNPs  we  also  did  not  analysed  haplotypes,  which  may  give  different 
outcomes. We do acknowledge and agree that there is an interaction between different cytokines 
and other genes with functional significance, which requires more precise evaluation.  
In conclusion, despite the great progress in pain treatment and management of multiple 
myeloma patients, there are a lot  of patients suffering from severe pain. Sociodemographics 
characteristics, clinical and psychological factors influence pain and its treatment. Our study 
gives the preliminary evidence that the SNPs in cytokine genes correlate with pain syndrome in 
multiple  myeloma  patients  and  analgesic response to radiotherapy, thus  it  may  be  useful to 
develop  risk  models  for  better  understanding  of  pain,  which  permits  a  better  and  more 
individualized therapy for MM patients. Future prospective studies with large sample of patients 
incorporating additional genetic markers are needed to validate our findings. 
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Izvod 
Regulacija sekrecije citokinina je pod genetičkom kontrolom preko polomorfizma kodirajuće i 
promoterske sekvence. SNP (polimorfizam jednog nukleotida) u region promoter različitih gena 
može da regulše koncentraciju citokinina u plazmi. Vršena su istraživanja da li SNP u IL-6 i IL-
10 citokinina može da utiče na bolnu reakciju posle radioterapije pri tretmanu bolne destrukcije 
kosti kod MM pacijenata. Vršena su ispitivanja 6 SNPs u region promoter gena IL-6 (-597 G/A, 
-572  G/C,  -174  G/C)  i  IL-10  (-592  A/C,  -819  C/T,  -1082  A/G)  kao  i  odnos  sa  različitim 
bolovima i korišćenim lekovima. Zaključeno je da  SNP u IL-6 i IL-10 citokina može da utiče na 
odgovor  bola  posle  radioterapije.  Pacijenti  sa  genotipom  IL-10  -1082  A/G  reaguju  bolje  na 
radioterapiju. 
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